Ngokophononongo olutsha olwandulelayo, abantwana kunye nolutsha abane-Tourette syndrome abanyangwa ngeyeza lokulinga elibizwa ngokuba yi-ecopipam banokuthi baphucule amanqaku kwiimvavanyo zobukhali be-tic kwiinyanga ezintathu kamva. Uphando olukhutshiweyo namhlanje, nge-30 kaMatshi 2022, luza kuboniswa kwiNtlanganiso yoNyaka ye-American Academy of Neurology's 74th Annual Meeting eSeattle, ngo-Epreli 2 ukuya kwi-7, 2022 kwaye phantse, nge-24 ukuya kwi-26 ka-Epreli 2022. ukuphazamiseka kwemithambo-luvo kubonakaliswa ziintshukumo zemoto kunye nezamazwi, eziziintshukumo eziphindaphindwayo kunye nokuvakala kwelizwi okubangelwa kukunqwenela okungenakuphikiswa ukuzivelisa.
"Iziphumo zethu ziyonwabisa, kuba zibonisa ukuba i-ecopipam ibonisa isithembiso njengonyango lokunciphisa inani, ukuphindaphinda kunye nobunzima be-tics abantu abancinci abanamava nge-Tourette syndrome," watsho umbhali ophononongayo uDonald L. Gilbert, MD, weSibhedlele saBantwana saseCincinnati. Iziko e-Ohio, kunye noMlingane we-American Academy of Neurology. Kuyinyani ngakumbi kuba abantu abaninzi abanesifo abathatha amayeza akhoyo ngoku basenazo iimpawu ezibaqobayo okanye bafumana ubunzima okanye ezinye iziphumo ebezingalindelekanga.
Uphando lujonge abantwana be-149 kunye nabaselula abaphakathi kweminyaka emithandathu kunye ne-17 abane-Tourette syndrome. Baye bahlula ngamaqela amabini: i-74 yaphathwa nge-ecopipam, i-75 kunye ne-placebo.
Abaphandi balinganise ubungqongqo bee-tics zabathathi-nxaxheba besebenzisa izikali ezimbini eziqhelekileyo zokulinganisa i-tic ekuqaleni kophononongo kwaye kwakhona kwiinyanga ezintathu kamva. Uvavanyo lokuqala lulinganisa i-motor and vocal tics kwaye lunamanqaku aphezulu angama-50. Uvavanyo lwesibini lujonga iimpawu ze-tic zizonke kunye nobukhulu bokukhubazeka okunxulumene ne-tic. Inomlinganiselo ophezulu we-100. Amanqaku aphezulu kulo naluphi na uvavanyo lubonisa iimpawu ezinzima kunye nefuthe elibi kubomi bemihla ngemihla.
Emva kweenyanga ezintathu, abaphandi bafumanisa ukuba iqela elithatha i-ecopipam linee-tics ezimbalwa kwaye lingaphantsi kwaye liqhuba ngcono ngokubanzi ngokwamanqaku ovavanyo omabini.
Ngokomyinge, abathathi-nxaxheba abathatha i-ecopipam baphucule i-motor kunye ne-vocal tic ukuqina kwamanqaku ukusuka kwi-35 ukuya kwi-24, ukuhla kwe-30%. Oko kuthelekiswa nabo bathatha i-placebos, abathe baphucuka ukusuka kumndilili wobuqatha bamanqaku angama-35 ukuya kuma-28 ngexesha elinye, ukuncipha nge-19%.
Xa abaphandi bajonga amanqaku ovavanyo lwesibini ukuvavanya ukusebenza ngokupheleleyo kwe-ecopipam, bafumanisa ukuba abo bathatha iyeza baphuculwe ukusuka kumyinge wamanqaku angama-68 ukuya kuma-46, ukuhla kwe-32%, xa kuthelekiswa nalabo bathatha indawo ye-placebo, abaphucule ukusuka kwi-avareji ye-66 ukuya kwi-54. i-avareji amanqaku 20 ukuya XNUMX, ukuncipha XNUMX%.
UGilbert waqaphela ukuba i-34% yabathathi-nxaxheba abathatha i-ecopipam baye bafumana iziphumo ebezingalindelekanga ezifana nentloko ebuhlungu kunye nokudinwa, ngelixa i-21% yabo bathatha i-placebos benzile.
"Uphando lwangaphambili lubonisa iingxaki nge-dopamine, i-neurotransmitter engqondweni, inokudibaniswa neempawu ze-Tourette syndrome, kwaye i-D1 dopamine receptors idlala indima ebalulekileyo," kusho uGilbert. "I-Dopamine receptors zifumaneka kwinkqubo ye-nervous central. Xa befumana i-dopamine, benza imiqondiso yemisebenzi eyahlukeneyo yengqondo neyomzimba njengokushukuma. Ii-receptors ezahlukeneyo zinceda ukulawula imisebenzi eyahlukeneyo. Ngelixa i-ecopipam isesigabeni sokuvavanya, iyona mayeza okuqala ukujolisa kwi-D1 receptor endaweni ye-D2 receptor, eyona nto ijoliswe ngamachiza okwangoku kwimarike. Iziphumo zethu zibonisa ukuba i-ecopipam ifanelwe kukufunda ngakumbi njengonyango olusebenzayo lweTourette syndrome kubantu abancinci kwikamva.
Umda wophononongo bubude beenyanga ezintathu. UGilbert uqaphele ukuba nangona iyinto eqhelekileyo kolu hlobo lophononongo, kuya kubaluleka ukufunda ukuba ukuphuculwa kweempawu kuqhubeka ixesha elide.
